Veracyte, Inc. has announced the pricing of an underwritten public offering of 7,432,433 shares of its common stock at a public offering price of US$74 per share. The gross proceeds to the Company from this offering, before deducting underwriting discounts and commissions and offering expenses payable by Veracyte, are expected to be approximately US$550 million. The public offering was upsized from the previously announced size of US$400 million in shares of common stock. All of the shares are being offered by the Company. In addition, the Company granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,114,864 shares of its common stock at the public offering price, less underwriting discounts and commissions.
Latham & Watkins LLP advised the underwriters in the transaction with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Denis Griffin and Briana Goncalves.